Swansea University (SU)

Expert:



Martin Clift
Associate Professor of In Vitro Systems for Particle/Fibre Toxicology

In vitro / in vivo extrapolation from cells to (animal to) human

Swansea University is a public higher-education and research institution located in South Wales (UK). It was established by Royal Charter in 1920 and has research excellence as one of three pillars of a strategic plan for future development. Exceptional performance by its Medical School in the last REF assessment (2nd in UK in Unit of Assessment 3) testifies to a first-class research environment – it was ranked joint first in the UK for research environment and second for research quality and impact, with 95% of the research submitted assessed as world-leading or internationally excellent. Life sciences and nanotoxicology research at Swansea are undertaken within the Institute of Life Sciences (ILS), where the multidisciplinary (Medicine, Engineering, Science) Centre for NanoHealth (CNH) is one of five major research facilities alongside eHealth and Informatics, Mass Spectrometry, Biomedical Laboratories and Joint Clinical Research Facilities. These collectively enable the delivery of research and innovation across the Medical School, with the Biomarkers and Genes theme encompassing work in areas that include genetic toxicology, and cancer with a strong focus on nanotoxicology.


Main activities within HARMLESS:

  • In vitro / in vivo extrapolation from cells to (animal to) human
  • Experimental (predictive in vitro models) and case-study work on nanomaterial safety
Top
get to know
HARM
LESS
EU-funded H2020 Research & Innovation Action addressing Safe-by-Design of multicomponent nanomaterials running from January 2021 - January 2025

FOLLOW US ON